Croma-Pharma Released New Dermal Filler
The company has introduced a new hyaluronic acid filler that replaces its previous version for midface and fold treatment.
Updated on Sept. 25, 2026 in Beauty
Live Poll
Do you trust that new medical aesthetic products represent real improvements for patients?
Croma-Pharma has launched saypha volume prime Lidocaine, a cross-linked hyaluronic acid filler designed for midface volumization and addressing nasolabial folds. This new product will gradually replace the company’s existing saypha volume Lidocaine across international markets.
Why it matters
This transition introduces a more versatile treatment option for patients seeking facial volumization, as the company updates its portfolio. The shift reflects a broader effort to standardize and expand the utility of available cosmetic injectables.
A clinical study involving nearly 500 patients demonstrated that the new filler maintains non-inferiority when compared to its predecessor. While these clinical findings support the new product's performance, long-term patient outcomes beyond the trial duration remain under investigation.
The players
Croma-Pharma
An Austrian pharmaceutical company specializing in the production of hyaluronic acid-based dermal fillers and aesthetic medicine products.
The details
The filler is composed of cross-linked hyaluronic acid, a substance that naturally occurs in the skin and provides structural support. By injecting this gel into the midface or along nasolabial folds, practitioners aim to restore volume and smooth skin texture. The new formulation is intended to be more versatile, offering expanded indications for cosmetic use compared to the product it replaces.
Timeline
September 25, 2026: Croma-Pharma announced the new dermal filler.
End of September 2026: The transition to the new product begins.
Health Landscape
This product launch marks the latest update to the cosmetic injectable market, which has seen significant shifts in formulation technology. It follows a period of rapid production scaling for Croma-Pharma, which produced over 130 million syringes in 2026.
If you are currently receiving treatments with saypha volume Lidocaine, consider asking your practitioner how this product transition may affect your future care sessions. It is important to discuss your aesthetic goals and any history of reactions to hyaluronic acid products with your doctor.
The takeaway
The replacement of this filler highlights the importance of staying informed about the products used in your cosmetic procedures. When considering any new injectable, always have a detailed conversation with your healthcare provider about how the treatment aligns with your specific facial anatomy.
Further reading
For more information on the latest advancements in dermatological aesthetics, explore our Beauty section.
Source note: This article includes information reported by Iberonews.
Live Poll
Do you trust that new medical aesthetic products represent real improvements for patients?
